CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 41 enrolled
Drug / intervention
Peginterferon alfa-2adrug
Likely dose
Peginterferon alfa-2a 450 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02736721
NCT02736721Phase 3Completed
CompareCT.gov

Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)

Hoffmann-La Roche·interventional·Posted Apr 13, 2016·Updated Sep 20, 2016

In Brief

A Phase 3 clinical trial evaluating Peginterferon alfa-2a for Myelogenous Leukemia, Chronic. Completed, enrolled 41 participants across 5 sites.

Detailed Summary

This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available), NO16006 (NCT number not available) or ML17228 (NCT number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelogenous Leukemia, Chronic
CountriesGermany
Collaborators--

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2016
Enrollment StartSep 1, 2003
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 10.2 years ago

Interventions

Peginterferon alfa-2adrug

Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.